ABPI response to NICE 5 year strategy

NICE has launched its 5-year strategy which it says will help to speed up patients’ access to the latest and most effective treatments.

In response, Richard Torbett, Chief Executive of the ABPI, said:

“Pharmaceutical companies are working on thousands of exciting new medicines and treatments, from rare disease gene therapies to mRNA vaccines for cancer. Today’s strategy sets out a positive vision for the future of NICE; one which will see it evolve with the science that makes these breakthroughs possible and build on its international reputation for producing evidence-based guidance.

“We will continue to work with NICE to ensure medicine appraisals remain robust, transparent, and in line with the latest science so that NHS patients can benefit from new medicines when they become available.”